A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide with placebo plus enzalutamide for patients with advanced prostate cancer.

Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Szczylik C, De Giorgi U, Joung JY, Fong PCC, Voog E, Jones RJ, Shore ND, Saad F, Dunshee C, Zschäbitz S, Oldenburg J, Lin X, Healy CG, Kalac M, Kennedy D, Fizazi K

Open source

DOI: 10.1080/14796694.2026.2668552
Published: 2026 Jun
Container: Future oncology (London, England)
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/14796694.2026.2668552,
  title = {A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide with placebo plus enzalutamide for patients with advanced prostate cancer.},
  author = {Agarwal N and Azad AA and Carles J and Fay AP and Matsubara N and Szczylik C and De Giorgi U and Joung JY and Fong PCC and Voog E and Jones RJ and Shore ND and Saad F and Dunshee C and Zschäbitz S and Oldenburg J and Lin X and Healy CG and Kalac M and Kennedy D and Fizazi K},
  year = {2026},
  journal = {Future oncology (London, England)},
  doi = {10.1080/14796694.2026.2668552},
  url = {https://doi.org/10.1080/14796694.2026.2668552}
}

RIS

TY  - JOUR
TI  - A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide with placebo plus enzalutamide for patients with advanced prostate cancer.
AU  - Agarwal N
AU  - Azad AA
AU  - Carles J
AU  - Fay AP
AU  - Matsubara N
AU  - Szczylik C
AU  - De Giorgi U
AU  - Joung JY
AU  - Fong PCC
AU  - Voog E
AU  - Jones RJ
AU  - Shore ND
AU  - Saad F
AU  - Dunshee C
AU  - Zschäbitz S
AU  - Oldenburg J
AU  - Lin X
AU  - Healy CG
AU  - Kalac M
AU  - Kennedy D
AU  - Fizazi K
PY  - 2026
JO  - Future oncology (London, England)
DO  - 10.1080/14796694.2026.2668552
UR  - https://doi.org/10.1080/14796694.2026.2668552
ER  -

APA

N, A., AA, A., J, C., AP, F., N, M., C, S., U, D. G., JY, J., PCC, F., E, V., RJ, J., ND, S., F, S., C, D., S, Z., J, O., X, L., CG, H., M, K., D, K., & K, F. (2026). A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide with placebo plus enzalutamide for patients with advanced prostate cancer.. Future oncology (London, England). https://doi.org/10.1080/14796694.2026.2668552

Source records

pubmed · retrieved 2026-09-25T16:33:55.175Z